Enzastaurin Versus Lomustine in Glioblastoma

Summary

This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).

Timeline

Start

2006-01

Primary completion

2007-08

Completion

2014-05

Outcome

Missed primary endpoint

paper 6-month PFS rate (P = .13) did not differ significantly between enzastaurin and lomustine, respectively. PMID 20124186 ↗

paper Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine PMID 20124186 ↗

Publications

• Results Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar 1;28(7):1168-74. doi: 10.1200/JCO.2009.23.2595. Epub 2010 Feb 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Lomustine	Small molecule	100 mg/m2	Oral
Comparator	Lomustine	Small molecule	130 mg/m2	Oral
Subject	enzastaurin	Small molecule	500 mg	Oral

Indications